This inventor holds 1 USPTO granted patent. Top assignee: General Electric Company. Active years: 2009.
Company Filing History:
Years Active: 2009
Title: Innovations by Ian Rowlandson in Long QT Syndrome Detection
Introduction
Ian Rowlandson is an accomplished inventor based in Milwaukee, WI (US). He has made significant contributions to the field of medical technology, particularly in the detection of long QT syndrome (LQTS). His innovative approach combines advanced data analysis with patient-specific characteristics to enhance diagnostic accuracy.
Latest Patents
Rowlandson holds a patent for a "System and method of serial comparison for detection of long QT syndrome (LQTS)." This patent describes a system that detects LQTS in patients by comparing collected ECG data to various databases. These databases include previous ECGs from the patient, a known acquired LQTS characteristics database, and a known genetic LQTS characteristics database. The method allows for the detection of changes in QT interval, T-wave morphology, and U-wave morphology, while also matching known genetic patterns of LQTS. The system is sensitive to patient gender and ethnicity, which are critical factors in LQTS diagnosis. Additionally, it can match QT duration to a database of drug effects and is designed for easy integration into existing ECG management systems.
Career Highlights
Rowlandson is associated with General Electric Company, where he applies his expertise in medical technology. His work focuses on improving patient outcomes through innovative diagnostic solutions. His patent reflects his commitment to advancing healthcare technology and enhancing the accuracy of LQTS detection.
Collaborations
Rowlandson has collaborated with notable colleagues, including Mark Robert Kohls and Joel Qiuzhen Xue. These partnerships have contributed to the development of cutting-edge technologies in the medical field.
Conclusion
Ian Rowlandson's contributions to the detection of long QT syndrome exemplify the impact of innovation in healthcare. His patented system not only enhances diagnostic capabilities but also prioritizes patient-specific factors, paving the way for more personalized medical care.